-
How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?
Thursday, December 23, 2021 - 4:01pm | 671Pfizer, Inc. (NYSE: PFE) announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for use by the U.S. Food and Drug Administration. The Pfizer Analysts: SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer. BofA...
-
Pfizer's COVID-19 Franchise Could Push Revenue Past $100B In 2022: Analyst
Tuesday, November 23, 2021 - 3:16pm | 614Pfizer, Inc. (NYSE: PFE) found huge success with its COVID-19 franchise that includes Comirnaty, the COVID-19 vaccine it co-developed with BioNTech SE (NASDAQ: BNTX), and its yet-to-be authorized oral COVID-19 pill Paxlovid. The Pfizer Analyst: SVB Leerink analyst Geoffrey Porges reiterated a...
-
Analyst Upgrades Sanofi On COVID-19 Vaccine Optimism
Monday, September 27, 2021 - 12:01pm | 436Sanofi SA (NASDAQ: SNY) shares traded higher by 0.4% on Monday after the company scored an analyst upgrade. The Analyst: SVB Leerink analyst Geoffrey Porges upgraded Sanofi from Market Perform to Outperform and raised his price target per U.S. ADR from $69.61 to $71.37. Related Link: Cigna Has...
-
What 3 FibroGen Analysts Are Expecting From Thursday's Roxadustat Adcom Verdict
Wednesday, July 14, 2021 - 5:04pm | 783FibroGen, Inc. (NASDAQ: FGEN) has a key catalyst Thursday when FDA's Cardiovascular and Renal Drugs Advisory Committee will issue its recommendation on the company's new drug application for roxadustat. The committee is scheduled to meet between 9:30 a.m. and 5:30 p.m. Roxadustat was ...
-
14 Biotech Stocks To Watch Over The Next 6 Months
Wednesday, June 23, 2021 - 12:44pm | 1851Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks. A case in point was the strong upside in Biogen Inc.'s (NASDAQ: BIIB) stock earlier this month when its Alzheimer's treatment Aduhelm was approved. Details on key catalytic events...
-
Breaking Down Novavax's Coronavirus Vaccine Data: 2 Analyst Takes
Friday, January 29, 2021 - 4:36pm | 833Novavax, Inc. (NASDAQ: NVAX) shares were roaring higher Friday after the company reported topline results from the late-stage trial of its coronavirus vaccine candidate in the U.K. The Novavax Analyst: H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating and $207 price target for...
-
Pfizer Analyst Breaks Down The FDA Process For Coronavirus Vaccine Candidate
Friday, December 11, 2020 - 3:45pm | 617Pfizer Inc. (NYSE: PFE) and BioNTech SE's – ADR (NASDAQ: BNTX) coronavirus vaccine candidate passed the Adcom test, with the FDA panel voting 17-4 in favor of its risk-benefit profile in individuals 16 and older. Here's SVB Leerink analyst Geoffrey Porges' take on the...
-
AstraZeneca Analyst Flags Lack Of Details In Interim COVID-19 Vaccine Data
Monday, November 23, 2020 - 3:21pm | 686AstraZeneca plc (NASDAQ: AZN) announced Monday interim Phase 3 data for its coronavirus vaccine candidate AZD1222 from studies conducted in the U.K. and Brazil, showing efficacy ranging between 62% and 90%. The AstraZeneca Analysts: SVB Leerink analyst Geoffrey Porges has an Outperform rating on...
-
Pfizer Analysts Raise Odds Of Success For Coronavirus Vaccine Candidate To 100%
Tuesday, November 10, 2020 - 11:49am | 537Pfizer Inc. (NYSE: PFE) reported Monday with strong Phase 3 interim efficacy data for its coronavirus vaccine candidate. The Pfizer Analysts: Morgan Stanley analyst David Risinger has an Equal-weight rating on Pfizer with a $42 price target. SVB Leerink analyst Geoffrey Porges...
-
Pfizer's COVID-19 Vaccine Candidate Primed For $3.5B In 2021 Sales: Analyst
Wednesday, October 21, 2020 - 10:45am | 504The mRNA coronavirus vaccine in development by Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) is poised for an emergency use authorization application, according to SVB Leerink. The Pfizer Analyst: Geoffrey Porges has a Market Perform rating on Pfizer shares. The Pfizer...
-
Moderna, Pfizer Have 2-Month Lead Over Coronavirus Vaccine Competitors: Analyst
Wednesday, October 7, 2020 - 4:49pm | 607The coronavirus vaccine race has two likely winners that have surged ahead in a crowded field, according to an SVB Leerink analyst. Pfizer, Moderna In The Lead: It now appears that Moderna Inc (NASDAQ: MRNA) and Pfizer Inc. (NYSE: PFE), along with its German partner BioNTech SE – ADR (...
-
Gilead Analysts Dissect Immunomedics Deal: 'Pricier But Bold Move Into Oncology'
Monday, September 14, 2020 - 12:47pm | 901Gilead Sciences, Inc. (NASDAQ: GILD) announced over the weekend a deal to buy Immunomedics, Inc. (NASDAQ: IMMU), which recently transitioned to a commercial-stage biopharma following FDA approval of its antibody-drug conjugate Trodelvy as a third-line treatment for metastatic triple-negative...
-
Gilead Analysts Downplay Q2 Miss Amid Remdesivir's COVID-19 Opportunity
Friday, July 31, 2020 - 12:56pm | 824Gilead Sciences, Inc. (NASDAQ: GILD) reported second-quarter revenues and earnings that trailed expectations. The Gilead Analysts Morgan Stanley analyst Matthew Harrison maintained an Equal-Weight rating and $79 price target for Gilead. Raymond James analyst Steven Seedhouse maintained a Market...
-
Pfizer Analysts See 'Surprisingly Strong' Vaccine Updates In Q2, Question Biopharma's Blockbuster Potential
Wednesday, July 29, 2020 - 11:30am | 1009Pfizer Inc. (NYSE: PFE) reported forecast-beating second-quarter results Tuesday and raised its full-year guidance. The beat-and-raise quarter — and an update on its coronavirus vaccine program — sent the biopharma's shares higher by 3.94%. The Pfizer Analysts: BofA Securities...
-
Moderna Looking To Price Its Coronavirus Vaccine At $50-$60, Significantly Above Rivals: FT
Tuesday, July 28, 2020 - 11:51pm | 497Moderna Inc (NASDAQ: MRNA) is looking to price its COVID-19 vaccine significantly ahead of rivals in between $50 and $60 per course, the Financial Times reported Wednesday. What Happened The Massachusetts-based biotechnology company is considering pricing a single dose of the...